Münevver Demir

Projektleiterin

Charité

Die Projekte von

Münevver Demir

B04

Exploiting

Targeting

Chronotherapie der mit metabolischer Dysfunktion assoziierten steatotischen Lebererkrankung (MASLD)

MASLD ist weit verbreitet und ein wesentlicher Risikofaktor für Leberzirrhose und Leberkrebs. Sport ist wirksam, wird aber oft durch mangelnde Compliance eingeschränkt. Dieses Projekt untersucht, wie das Timing von Sport mit den circadianen Hepatozyten-Uhren interagiert, um Stoffwechsel und MASLD-Verlauf zu beeinflussen.

Chronotherapie der mit metabolischer Dysfunktion assoziierten steatotischen Lebererkrankung (MASLD)

MASLD ist weit verbreitet und ein wesentlicher Risikofaktor für Leberzirrhose und Leberkrebs. Sport ist wirksam, wird aber oft durch mangelnde Compliance eingeschränkt. Dieses Projekt untersucht, wie das Timing von Sport mit den circadianen Hepatozyten-Uhren interagiert, um Stoffwechsel und MASLD-Verlauf zu beeinflussen.

Die Publikationen von

Münevver Demir

Targeting

Detecting

Hepatocyte Circadian Clocks Control Cholesterol Metabolism and Protect From Metabolic Dysfunction–Associated Steatohepatitis

May 12, 2026

Cellular and Molecular Gastroenterology and Hepatology

The circadian clock synchronizes physiological processes with the 24-hour light–dark cycle. Clock disruption contributes to metabolic disorders, including metabolic dysfunction–associated steatohepatitis. We investigated the role of the hepatocyte clock in metabolic dysfunction–associated steatohepatitis using hepatocyte-specific Bmal1 deletion (Hep-Bmal1KO) mice. Hep-Bmal1KO mice showed faster metabolic dysfunction–associated steatohepatitis progression with increased hepatic cholesterol, inflammation, and fibrosis. Transcriptomic and lipidomic analyses revealed dysregulated cholesterol metabolism in Hep-Bmal1KO mice, marked by reduced expression and disrupted rhythmicity of key cholesterol-related genes. Bioinformatic analyses identified Chrebp as a potential coregulator of these transcriptional changes. In an in vitro model with palmitate exposure and gene silencing, we found that Bmal1, but not Chrebp, regulated cholesterol accumulation, indicating Bmal1’s specific role in hepatic cholesterol metabolism. Translating our findings to a human patient cohort revealed a significantly shifted circadian phase, despite no marked effect on hepatic cholesterol levels in the livers of patients with more advanced liver disease (ie, metabolic dysfunction–associated steatohepatitis) compared with simple steatosis. Taken altogether, our findings offer a roadmap to understand the hepatocyte clock’s role in metabolic dysfunction–associated steatohepatitis and its potential as a therapeutic target.

Exploiting

Targeting

The role of the circadian clock in the development, progression, and treatment of non-alcoholic fatty liver disease

January 4, 2023

Acta Physiologica

The circadian clock comprises a cellular endogenous timing system coordinating the alignment of physiological processes with geophysical time. Disruption of circadian rhythms has been associated with several metabolic diseases. In this review, we focus on liver as a major metabolic tissue and one of the most well-studied organs with regard to circadian regulation. We summarize current knowledge about the role of local and systemic clocks and rhythms in regulating biological functions of the liver. We discuss how the disruption of circadian rhythms influences the development of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). We also critically evaluate whether NAFLD/NASH may in turn result in chronodisruption. The last chapter focuses on potential roles of the clock system in prevention and treatment of NAFLD/NASH and the interaction of current NASH drug candidates with liver circadian rhythms and clocks. It becomes increasingly clear that paying attention to circadian timing may open new avenues for the optimization of NAFLD/NASH therapies and provide interesting targets for prevention and treatment of these increasingly prevalent disorders.

Keywords: NAFLD; NASH; chronotherapy; circadian rhythms; clock genes; liver; metabolic-associated fatty liver disease (MAFLD).

Exploiting

Targeting

Nonalcoholic Steatohepatitis Disrupts Diurnal Liver Transcriptome Rhythms in Mice

December 31, 2023

CMGH

Background & aims: The liver ensures organismal homeostasis through modulation of physiological functions over the course of the day. How liver diseases such as nonalcoholic steatohepatitis (NASH) affect daily transcriptome rhythms in the liver remains elusive.

Methods: To start closing this gap, we evaluated the impact of NASH on the diurnal regulation of the liver transcriptome in mice. In addition, we investigated how stringent consideration of circadian rhythmicity affects the outcomes of NASH transcriptome analyses.

Results: Comparative rhythm analysis of the liver transcriptome from diet-induced NASH and control mice showed an almost 3-hour phase advance in global gene expression rhythms. Rhythmically expressed genes associated with DNA repair and cell-cycle regulation showed increased overall expression and circadian amplitude. In contrast, lipid and glucose metabolism-associated genes showed loss of circadian amplitude, reduced overall expression, and phase advances in NASH livers. Comparison of NASH-induced liver transcriptome responses between published studies showed little overlap (12%) in differentially expressed genes (DEGs). However, by controlling for sampling time and using circadian analytical tools, a 7-fold increase in DEG detection was achieved compared with methods without time control.

Conclusions: NASH had a strong effect on circadian liver transcriptome rhythms with phase- and amplitude-specific effects for key metabolic and cell repair pathways, respectively. Accounting for circadian rhythms in NASH transcriptome studies markedly improves DEG detection and enhances reproducibility.

Keywords: Circadian Bioinformatics; Circadian Clock; Circadian RNAseq; Energy Metabolism; Nonalcoholic Fatty Liver Disease (NAFLD).